Diligence memo · auto-generated · as of July 2, 2026
Ascus Biosciences, Inc.
Ascus Biosciences, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ascus Biosciences, Inc. operates in Biotech / Pharma, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ascus Biosciences, Inc. has raised $29M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2016-04-11.
Most recent recorded round closed around 2019-05-31.
Valuation (modeled)modeled
Provath models Ascus Biosciences, Inc. at approximately $168M (range $5.6M–$911M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series A Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 7.1 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 82% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 78% of those peers.
Closest niche peers: Advanced Bio Development, Inc., Generian Pharmaceuticals, Inc., Teiko Bio, Inc., Singular Bio, Inc., Genomic Prediction, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.